EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mitochondrial dynamics as a novel treatment strategy for triple‐negative breast cancer

Yuechen Wang, Narumi Harada-Shoji iD, Narufumi Kitamura, Yuto Yamazaki, Akiko Ebata, Masakazu Amari, Mika Watanabe, Minoru Miyashita, Hiroshi Tada, Takaaki Abe, Takashi Suzuki iD, Kohsuke Gonda und 1 weitere

Cancer Medicine · 2024-01 · 13 (2)

DOI: 10.1002/cam4.6987 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 09.02.2024. Verfasst von Yuechen Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Triple‐negative breast cancer (TNBC), recognized as the most heterogeneous type of breast cancer (BC), exhibits a worse prognosis than other subtypes. Mitochondria dynamics play a vital role as mediators in tumorigenesis by adjusting to the cell microenvironments. However, the relationship between mitochondrial dynamics and metabophenotype exhibits discrepancies and divergence across various research and BC models. Therefore, this study aims to explore the role of mitochondrial dynamics in TNBC drug resistance and tumorigenesis.

Methods

The Wst‐8 test was conducted to assess doxorubicin sensitivity in HCC38, MDA‐MB‐231 (TNBC), and MCF‐7 (luminal). Confocal microscopy and FACS were used to quantify the mitochondrial membrane potential (ΔφM), mitophagy, and reactive oxygen species (ROS) production. Agilent Seahorse XF Analyzer was utilized to measure metabolic characteristics. Dynamin‐related protein‐1 (DRP1), Parkin, and p62 immunohistochemistry staining were performed using samples from 107 primary patients with BC before and after neoadjuvant chemotherapy (NAC).

Results

MDA‐MB‐231, a TNBC cell line with reduced sensitivity to doxorubicin, reduced ΔφM, and enhanced mitophagy to maintain ROS production through oxidative phosphorylation (OXPHOS)‐based metabolism. HCC38, a doxorubicin‐sensitive cell line, exhibited no alterations in ΔφM or mitophagy. However, it demonstrated an increase in ROS production and glycolysis. Clinicopathological studies revealed that pretreatment (before NAC) expression of DRP1 was significant in TNBC, as was pretreatment expression of Parkin in the hormone receptor‐negative group. Furthermore, low p62 levels seem to be a risk factor for recurrence‐free survival.

Conclusion

Our findings indicated that the interplay between mitophagy, linked to a worse clinical prognosis, and OXPHOS metabolism promoted chemotherapy resistance in TNBC. Mitochondrial fission is prevalent in TNBC. These findings suggest that targeting the unique mitochondrial metabolism and dynamics in TNBC may offer a novel therapeutic strategy for patients with TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsHumansMitochondrial DynamicsCell Line, TumorReactive Oxygen SpeciesDoxorubicinUbiquitin-Protein LigasesCarcinogenesisTumor Microenvironment

Stichwörter der Autor:innen

breast cancerdrug resistancemitochondriamitophagy

Substanzen

Reactive Oxygen SpeciesDoxorubicinUbiquitin-Protein Ligases

Autor:innen und Institutionen

  • Department of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Department of Medical Physics, Graduate School of Medicine, Tohoku University, Sendai, Japan.
  • Department of Pathology, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Department of Breast Surgery, Tohoku Kosai Hospital, Sendai, Japan.
  • Department of Pathology, Tohoku Kosai Hospital, Sendai, Japan.
  • Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

ORCID-Profile: Narumi Harada-Shoji, Takashi Suzuki

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Wang, Y., Harada-Shoji, N., Kitamura, N., Yamazaki, Y., Ebata, A., Amari, M., Watanabe, M., Miyashita, M., Tada, H., Abe, T., Suzuki, T., Gonda, K., & Ishida, T. (2024). Mitochondrial dynamics as a novel treatment strategy for triple‐negative breast cancer. Cancer Medicine, 13(2). https://doi.org/10.1002/cam4.6987

Vancouver

Wang Y, Harada-Shoji N, Kitamura N, Yamazaki Y, Ebata A, Amari M, et al. Mitochondrial dynamics as a novel treatment strategy for triple‐negative breast cancer. Cancer Medicine. 2024;13(2). doi:10.1002/cam4.6987

BibTeX
@article{Wang2024,
  author = {Wang, Yuechen and Harada-Shoji, Narumi and Kitamura, Narufumi and Yamazaki, Yuto and Ebata, Akiko and Amari, Masakazu and Watanabe, Mika and Miyashita, Minoru and Tada, Hiroshi and Abe, Takaaki and Suzuki, Takashi and Gonda, Kohsuke and Ishida, Takanori},
  title = {Mitochondrial dynamics as a novel treatment strategy for triple‐negative breast cancer},
  journal = {Cancer Medicine},
  year = {2024},
  volume = {13},
  number = {2},
  doi = {10.1002/cam4.6987}
}
Kostenlos starten →